Investigating how purinergic receptors affect multiple myeloma cells
Purinergic Receptors in Myeloma
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11058658
This study is looking at how we can target specific receptors in cancer cells to help kill them or stop multiple myeloma from getting worse, using new models that mimic real patients to find better treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11058658 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how certain receptors in malignant plasma cells can be targeted to induce their death or prevent the progression of multiple myeloma, a serious blood cancer. The study aims to explore the role of extracellular ATP and specific receptors in the survival of these cancer cells within the bone marrow. By using innovative models, including patient-derived xenografts, the research will investigate the mechanisms that allow myeloma cells to evade death and how disrupting these signals could lead to new treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple myeloma or those with premalignant plasma cell conditions.
Not a fit: Patients with other types of blood cancers or those not diagnosed with plasma cell disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that more effectively eliminate multiple myeloma cells and reduce the risk of relapse.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALLMAN, DAVID M — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: ALLMAN, DAVID M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: advanced disease